Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2022 after Market Close on March 8, 2022

Rhea-AI Summary

Avid Bioservices (NASDAQ:CDMO) will report its Q3 fiscal year 2022 financial results on March 8, 2022, after market close. A conference call will follow at 1:30 PM PT, where senior management will discuss the results and corporate developments. Avid, an S&P SmallCap 600 company, has 28 years of experience in CGMP manufacturing and offers a range of services to the biotechnology and biopharmaceutical industries. These services include process development, clinical and commercial manufacturing, and regulatory support.

TUSTIN, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the third quarter of fiscal year 2022 on March 8, 2022 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the third quarter and review recent corporate developments.

To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/investor-events.

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Avid Bioservices call.

About Avid Bioservices, Inc.

Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 28 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com

FAQ

When will Avid Bioservices report its Q3 2022 financial results?

Avid Bioservices will report its Q3 2022 financial results on March 8, 2022, after market close.

What time is the Avid Bioservices conference call for Q3 2022?

The conference call for Avid Bioservices' Q3 2022 results is scheduled for 1:30 PM Pacific Time on March 8, 2022.

How can I access Avid Bioservices' Q3 2022 financial results webcast?

You can access the webcast for Avid Bioservices' Q3 2022 financial results by visiting their investor events page.

What services does Avid Bioservices provide?

Avid Bioservices provides a comprehensive range of process development, CGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries.